- Home
- RITR vs TRVI Comparison
RITR vs TRVI Comparison
Compare RITR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- TRVI
- Stock Information
- Founded
- RITR 2015
- TRVI 2011
- Country
- RITR Hong Kong
- TRVI United States
- Employees
- RITR N/A
- TRVI N/A
- Industry
- RITR
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- TRVI Health Care
- Exchange
- RITR NYSE
- TRVI Nasdaq
- Market Cap
- RITR 249.8M
- TRVI 211.4M
- IPO Year
- RITR 2024
- TRVI 2019
- Fundamental
- Price
- RITR $3.98
- TRVI $4.05
- Analyst Decision
- RITR
- TRVI Strong Buy
- Analyst Count
- RITR 0
- TRVI 8
- Target Price
- RITR N/A
- TRVI $9.31
- AVG Volume (30 Days)
- RITR 206.2K
- TRVI 4.2M
- Earning Date
- RITR 02-15-2025
- TRVI 11-06-2024
- Dividend Yield
- RITR N/A
- TRVI N/A
- EPS Growth
- RITR N/A
- TRVI N/A
- EPS
- RITR 0.04
- TRVI N/A
- Revenue
- RITR $32,198,033.00
- TRVI N/A
- Revenue This Year
- RITR N/A
- TRVI N/A
- Revenue Next Year
- RITR N/A
- TRVI N/A
- P/E Ratio
- RITR $91.73
- TRVI N/A
- Revenue Growth
- RITR 74.80
- TRVI N/A
- 52 Week Low
- RITR $2.35
- TRVI $1.27
- 52 Week High
- RITR $8.75
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- TRVI 64.87
- Support Level
- RITR N/A
- TRVI $4.08
- Resistance Level
- RITR N/A
- TRVI $4.68
- Average True Range (ATR)
- RITR 0.00
- TRVI 0.38
- MACD
- RITR 0.00
- TRVI 0.15
- Stochastic Oscillator
- RITR 0.00
- TRVI 73.00
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.